PMN 8-K: Press release filed reporting Q2 and first-half 2025 results

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. filed a Form 8-K announcing it issued a press release reporting its financial condition and results for the three and six months ended June 30, 2025. The filing states the press release is available on the company's website under Investors/Financial Results and that a copy is furnished as Exhibit 99.1 to the report. The 8-K identifies the company as a Nasdaq-listed registrant trading as PMN on The Nasdaq Capital Market and indicates the registrant has the status of an emerging growth company.

The filing itself does not include the financial statements or numerical results; investors are directed to the press release (Exhibit 99.1) for the detailed financial figures and discussion of the companys performance for the reported periods.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished as an exhibit; the filing contains no financial figures, so investors must read Exhibit 99.1 for results.

The Form 8-K notifies the market that ProMIS released its quarterly results via press release and furnished that release as Exhibit 99.1. Because this filing does not include the underlying numerical statements or commentary, it is a procedural disclosure confirming the availability of results rather than presenting new quantitative data within the filing itself. Market participants should review the press release on the company's Investor Relations page to evaluate revenue, net income/loss, cash position, and any commentary on operating drivers or reserves.

Corporate Governance Expert

TL;DR: Compliance-focused filing that furnishes the press release as an exhibit and affirms public disclosure practices; no governance changes disclosed.

The company used the Form 8-K to furnish a press release reporting interim financial results and to make the release publicly accessible via its website. The filing reflects standard disclosure practice for timely distribution of material financial information and includes the exhibit reference for regulatory traceability. No executive changes, restatements, waivers, or material contracts are disclosed in this document.

0001374339false00013743392025-08-132025-08-13

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

PROMIS NEUROSCIENCES INC.

(Exact name of registrant as specified in its charter)

​

Ontario, Canada		001-41429		98-0647155
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

​

​

Suite 200, 1920 Yonge Street, Toronto, Ontario				M4S 3E2
(Address of principal executive offices)				(Zip Code)

​

Registrant’s telephone number, including area code: (416) 847-6898

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Shares, no par value per share	​	PMN		The Nasdaq Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 2.02Results of Operations and Financial Condition

On August 13, 2025, ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three and six months ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this report and is incorporated by reference into this Item 2.02.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

​	​	​
Exhibit No.		Description
99.1	​	Press Release dated August 13, 2025
104	​	Cover Page Interactive Data File (embedded within Inline XBRL document)

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	PROMIS NEUROSCIENCES INC.
​	​	​
Date: August 13, 2025	By:	/s/ Neil Warma
​	​	Name: Neil Warma
​	​	Title: Chief Executive Officer

​

​

​

FAQ

Where can I find ProMIS Neurosciences (PMN) Q2 2025 results?

The company states the press release reporting results for the three and six months ended June 30, 2025 is available on its website under Investors/Financial Results and is furnished as Exhibit 99.1.

Does the Form 8-K include numerical financial statements for PMN?

No. The Form 8-K only states that a press release reporting the financial condition and results is furnished as Exhibit 99.1; the filing itself does not contain the numerical statements.

What exchange and ticker does ProMIS Neurosciences use?

The filing shows ProMIS Neurosciences trades as PMN on The Nasdaq Capital Market.

Is ProMIS Neurosciences identified as an emerging growth company in the filing?

Yes. The filing indicates the registrant has checked the box identifying it as an emerging growth company.

Which exhibit contains the press release referenced in the 8-K?

The press release is furnished as Exhibit 99.1 to the Form 8-K.